|
EspAddText
EspRemoveText
|
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations
|
Response to consultation
|
2014
|
|
EspAddText
EspRemoveText
|
Proposed amendments to the marihuana for medical purposes regulations
|
Response to consultation
|
2014
|
|
EspAddText
EspRemoveText
|
Tamper Resistance under the Controlled Drugs and Substances Act
|
Response to consultation
|
2014
|
|
EspAddText
EspRemoveText
|
CMA's Response to Health Canada's Public Consultation Guide to New Authorities in reference to Bill C-17, Protecting Canadians from Unsafe Drugs Act
(Vanessa's Law)
|
Response to consultation
|
2015
|
|
EspAddText
EspRemoveText
|
Regulatory framework for the mandatory reporting of adverse drug reactions and medical device incidents by provincial and territorial healthcare institutions.
|
Response to consultation
|
2016
|
|
EspAddText
EspRemoveText
|
Consultation on the prescription drug list: Naloxone
|
Response to consultation
|
2016
|
|
EspAddText
EspRemoveText
|
Health Canada’s Consultation on “Plain and Standardized Packaging”
|
Response to consultation
|
2016
|
|
EspAddText
EspRemoveText
|
Legalization, regulation and restriction of access to marijuana
|
Response to consultation
|
2016
|
|
EspAddText
EspRemoveText
|
Regulation of Self-Care Products in Canada
|
Response to consultation
|
2016
|
|
EspAddText
EspRemoveText
|
Consultation on the renewal of Federal Tobacco Control Strategy
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
Federal Monitoring and Reporting Regime for MAID
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
CMA response to patented medicines regulations consultations
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
Non-prescription availability of low-dose codeine products
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
Excise duty framework for cannabis products
|
Response to consultation
|
2017
|
|
EspAddText
EspRemoveText
|
Proposed approach to the regulation of cannabis
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Federal monitoring of medical assistance in dying regulations
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Consultation on proposed front-of-package labelling
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on restriction of marketing and advertising of opioids
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on regulatory amendments regarding tramadol
|
Response to consultation
|
2018
|
|
EspAddText
EspRemoveText
|
Health Canada consultation on tobacco products regulations (plain and standardized appearance)
|
Response to consultation
|
2018
|